SNDX
- Syndax Pharmaceuticals, Inc.
()
Overview
Company Summary
Syndax Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing innovative therapies for cancer treatment. The company specializes in the discovery and development of drugs that target specific molecular pathways associated with cancer.
Syndax employs a unique approach by studying and understanding the interaction between cancer cells and the body's immune system. They aim to develop therapies that can modulate these interactions to enhance the body's natural defense mechanisms against cancer cells.
The company's pipeline includes a range of drug candidates at various stages of development, targeting multiple types of cancer. Their lead product candidate, entinostat, is being investigated as a potential treatment for breast cancer, lung cancer, and other solid tumors. Entinostat is designed to act as an epigenetic modulator, meaning it can control the expression of certain genes involved in cancer progression.
Syndax also collaborates with other pharmaceutical companies and research institutions to explore combination therapies that can improve patient outcomes. By combining entinostat with other drugs, they aim to enhance the effectiveness of treatments and potentially overcome resistance to existing therapies.
Overall, Syndax Pharmaceuticals is dedicated to advancing the field of cancer treatment through innovative drug discovery and development, with the ultimate goal of improving patient outcomes and quality of life.